What question did this study set out to answer?

To examine the pathophysiological role of the renin-angiotensin aldosterone system in hypertensive cardiovascular and renal disorders and evaluate pharmacologic strategies that inhibit this hormonal cascade.

October 1, 2007Journal of Managed Care PharmacyOpen Access

The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

SASteven A. AtlasGeneral / Preventive / Lipids

Discussion

Member takes

Implication

Should not yet change RAAS monotherapy practice; leaves open whether dual blockade or aliskiren adds benefit in cardiovascular and renal disease.

Key Points

To examine the pathophysiological role of the renin-angiotensin aldosterone system in hypertensive cardiovascular and renal disorders and evaluate pharmacologic strategies that inhibit this hormonal cascade.
Reviewed physiological mechanisms of the enzymatic cascade, focusing on the synthesis of angiotensin I from angiotensinogen via renin and subsequent conversion to angiotensin II by ACE.
Synthesized findings from preclinical and clinical investigations assessing the efficacy of beta-blockers, ACE inhibitors, angiotensin receptor blockers, and direct renin inhibitors.
Renin-mediated generation of angiotensin II promotes systemic vasoconstriction and fluid retention, driving the pathogenesis of hypertension and associated organ damage.
Treatment with ACE inhibitors and ARBs confers substantial cardiovascular and renal protection, but monotherapy achieves only incomplete suppression of the hormonal cascade.
Enhanced therapeutic strategies such as combination ACE inhibitor and ARB therapy or direct renin inhibition with aliskiren achieve broader system blockade, offering potential incremental clinical efficacy.

Cite This Study

Steven A. Atlas (2007) studied this question.

synapsesocial.com/papers/6a6fa693f44fa9f079dd1d8c https://doi.org/10.18553/jmcp.2007.13.s8-b.9

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

October 1, 2007Journal of Managed Care PharmacyOpen Access

The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

SASteven A. AtlasGeneral / Preventive / Lipids

Discussion

Member takes

Implication

Should not yet change RAAS monotherapy practice; leaves open whether dual blockade or aliskiren adds benefit in cardiovascular and renal disease.

Key Points

To examine the pathophysiological role of the renin-angiotensin aldosterone system in hypertensive cardiovascular and renal disorders and evaluate pharmacologic strategies that inhibit this hormonal cascade.
Reviewed physiological mechanisms of the enzymatic cascade, focusing on the synthesis of angiotensin I from angiotensinogen via renin and subsequent conversion to angiotensin II by ACE.
Synthesized findings from preclinical and clinical investigations assessing the efficacy of beta-blockers, ACE inhibitors, angiotensin receptor blockers, and direct renin inhibitors.
Renin-mediated generation of angiotensin II promotes systemic vasoconstriction and fluid retention, driving the pathogenesis of hypertension and associated organ damage.
Treatment with ACE inhibitors and ARBs confers substantial cardiovascular and renal protection, but monotherapy achieves only incomplete suppression of the hormonal cascade.
Enhanced therapeutic strategies such as combination ACE inhibitor and ARB therapy or direct renin inhibition with aliskiren achieve broader system blockade, offering potential incremental clinical efficacy.

Cite This Study

Steven A. Atlas (2007) studied this question.

synapsesocial.com/papers/6a6fa693f44fa9f079dd1d8c https://doi.org/10.18553/jmcp.2007.13.s8-b.9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark